À retenir
In a randomized trial of 72 people with chronic insomnia in Beijing, ear-based vagus nerve stimulation (taVNS) lowered the PSQI sleep score 4.2 points more than sham (95% CI -5.9 to -2.6; P < .001). The trial was small, single-center, and the sham group also improved, so wider benefit is unproven.
Study design
Essai randomisé
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Chronic insomnia is hard to treat with drugs and talk therapy alone, and randomized evidence for transcutaneous auricular vagus nerve stimulation (taVNS), a device that sends mild current to the ear, was lacking. The authors tested its efficacy and safety against sham stimulation.
Population et méthode
Randomized clinical trial at a single center in Beijing, China, from October 2021 to December 2022. Adults with chronic insomnia disorder and a Pittsburgh Sleep Quality Index (PSQI) of at least 8 were allocated 1:1 to active or sham taVNS, 30 minutes per session, twice a day, 5 consecutive days a week, for 8 weeks of treatment with 12 weeks of follow-up. The primary outcome was the mean change in PSQI from baseline through week 8; secondary outcomes covered mental health, sleepiness and fatigue, and safety. Registered as ChiCTR2100051319.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 172 participants were randomized: 36 to active taVNS (mean age 45.2, 27 [75.0%] female) and 36 to sham (mean age 44.6, 31 [86.1%] female); 68 completed the 8-week intervention.
- 2PSQI fell by 8.2 points (95% CI -9.3 to -7.0) with taVNS and by 3.9 points (95% CI -5.1 to -2.7) with sham, so both groups improved.
- 3The between-group difference was 4.2 points (95% CI -5.9 to -2.6; P < .001; Cohen d 1.2), larger than the 2.5-point minimal clinically important difference.
- 4Secondary outcomes, including mental health and fatigue, showed similar favorable results, and the effect was sustained through the 20-week study period.
Limites et incertitude
- 1Only 72 people were randomized at one center in Beijing, so the findings may not apply to other populations; the authors call for larger multicenter trials.
- 2Sleep quality was scored by a questionnaire (PSQI) rather than objectively recorded sleep, and the abstract does not say whether participants could tell which device they had.
- 3The sham group improved by 3.9 points, so a notable part of the change may come from expectation or the treatment routine rather than the stimulation itself.
- 4This reading is based on the abstract only.
Mise en perspective
This is an encouraging early signal that stimulating the ear could ease insomnia, but a single small trial is not enough to recommend a device. Treatment choices for chronic insomnia, including whether to use a taVNS device, should be made with a clinician.
Vos données
The trial judged sleep by the PSQI questionnaire, so your own check could be a weekly PSQI-style self-rating or sleep diary. Wearables can show total sleep time and bedtime consistency, but they estimate sleep stages poorly. Compare your own weeks on the same device and look at trends rather than single nights.
Comprendre ce type de preuve
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Importance
Evidence from randomized clinical trials of transcutaneous auricular vagus nerve stimulation (taVNS) for chronic insomnia disorder is lacking.
Objective
To evaluate the efficacy and safety of taVNS for chronic insomnia compared with the sham taVNS.
Design, setting, and participants
This randomized clinical trial was conducted from October 2021 to December 2022 at a single center in Beijing, China. Patients with chronic insomnia disorder with a Pittsburgh Sleep Quality Index (PSQI) of at least 8 were enrolled. Statistical analysis was performed from June to September 2023.
Interventions
Patients were allocated to the active taVNS group or sham taVNS group with a 1:1 ratio. Both groups received the stimulation for 30 minutes each time, twice a day, 5 consecutive days a week, with an 8-week treatment and a 12-week follow-up.
Main outcomes and measures
The primary end point was the mean change from baseline through week 8 in PSQI scores. Minimal clinically important difference was 2.5 points. Secondary outcomes included mental health, sleepiness, and fatigue. Safety was also evaluated.
Results
A total of 72 participants were randomized to either active taVNS group (36 participants; mean [SD] age, 45.2 [14.5] years; 27 [75.0%] female) or the sham taVNS group (36 participants; mean [SD] age, 44.6 [13.9] years; 31 [86.1%] female); 68 participants completed the 8-week intervention. The least-square mean changes from baseline to week 8 in PSQI were -8.2 (95% CI, -9.3 to -7.0) points in the taVNS group and -3.9 (95% CI, -5.1 to -2.7) points in the sham group. Both groups experienced statistically significant improvements from before to after the intervention. However, active taVNS showed a clinically meaningful 4.2-point greater reduction (95% CI, -5.9 to -2.6 points; P < .001; Cohen d effect size, 1.2) in PSQI compared with the sham group (minimal clinically important difference = 2.5 points). Secondary outcomes, including mental health and fatigue, showed similar favorable results. The efficacy of taVNS was sustained throughout the 20-week study period.
Conclusions and relevance
In this randomized clinical trial, taVNS significantly reduced insomnia severity. Clinically meaningful enhancements in PSQI scores were observed compared with sham stimulation, with the benefits of taVNS sustained over a 20-week period. Future multicenter clinical trials with large sample sizes are needed to validate its effectiveness across diverse populations.
Trial registration
Chinese Clinical Trial Registry: ChiCTR2100051319.
Sources et attribution
Transcutaneous Auricular Vagus Nerve Stimulation for Chronic Insomnia Disorder: A Randomized Clinical Trial.
Zhang S, Zhao Y, Qin Z, Han Y, He J, Zhao B, Wang L, Duan Y, Huo J, Wang T, Wang Y, Rong P.
JAMA network open · 2024-12-02
DOI: 10.1001/jamanetworkopen.2024.51217 ↗PubMed · 39680406 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Exercise improved sleep-quality scores in adults 45 and older with sleep disorders
Pooling 23 randomized trials with 1,478 adults aged 45 to 77 who had sleep disorders, exercise improved Pittsburgh Sleep Quality Index scores (SMD 0.62, 95% CI 0.40–0.83), and aerobic exercise showed the largest effect in the network analysis (SMD 1.34, 95% CrI 0.86–1.82). Certainty was low to moderate, the outcomes were questionnaires, and the best weekly dose of about 539 MET-min/week is a model estimate, not a prescription.
Journal of Exercise Science & Fitness
Sleep regularity tracked mortality more closely than sleep duration in 60,977 UK adults
Among 60,977 UK Biobank adults who wore a wrist accelerometer for a week, the most regular fifth of sleepers had a fully adjusted all-cause mortality HR of 0.70 (95% CI 0.59–0.83) against the least regular fifth, over about 6.3 years and 1859 deaths. Regularity fitted the data better than sleep duration, but the study is observational and rests on one week of sleep data.
Sleep
Sleep extension cut daily energy intake by about 270 kcal in adults with overweight
In 80 adults with overweight who usually slept under 6.5 hours, two weeks of sleep-extension counselling added about 1.2 hours of sleep and lowered measured energy intake by 270.4 kcal/d versus control (95% CI −393.4 to −147.4). The trial was short, single-centre and in a narrow group, so it does not show lasting weight loss or any benefit for people who already sleep enough.
JAMA Internal Medicine
Six hours or less of sleep at 50 and 60 linked to higher dementia risk
In 7959 British civil servants followed for about 25 years, sleeping six hours or less at age 50 (HR 1.22, 95% CI 1.01–1.48) or age 60 (HR 1.37, 1.10–1.72) was linked to a higher dementia rate than sleeping seven hours, and persistent short sleep gave an HR of 1.30 (1.00–1.69). Sleep was mostly self-reported and the study is observational, so early brain disease or other factors may explain part of the link.
Nature Communications

